First Trust Advisors LP Reduces Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

First Trust Advisors LP cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 13.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 47,824 shares of the medical instruments supplier’s stock after selling 7,367 shares during the quarter. First Trust Advisors LP owned about 0.21% of LeMaitre Vascular worth $4,407,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Barclays PLC raised its position in shares of LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of LeMaitre Vascular by 5.2% in the third quarter. Franklin Resources Inc. now owns 12,646 shares of the medical instruments supplier’s stock worth $1,165,000 after buying an additional 627 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of LeMaitre Vascular by 2.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 24,770 shares of the medical instruments supplier’s stock worth $2,282,000 after buying an additional 677 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in shares of LeMaitre Vascular by 11.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 19,942 shares of the medical instruments supplier’s stock valued at $1,837,000 after buying an additional 2,094 shares during the last quarter. Finally, Annex Advisory Services LLC increased its position in shares of LeMaitre Vascular by 5.9% in the 4th quarter. Annex Advisory Services LLC now owns 31,677 shares of the medical instruments supplier’s stock valued at $2,919,000 after acquiring an additional 1,769 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on LMAT shares. Wells Fargo & Company began coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target on the stock. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus target price of $98.14.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $90.24 on Friday. The stock has a market capitalization of $2.04 billion, a P/E ratio of 49.31, a PEG ratio of 2.22 and a beta of 0.89. The business has a 50 day simple moving average of $86.09 and a two-hundred day simple moving average of $93.42. LeMaitre Vascular, Inc. has a 12 month low of $65.16 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. During the same period in the prior year, the company posted $0.44 earnings per share. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular’s payout ratio is currently 41.24%.

Insider Buying and Selling at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.